Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Raymond Stevenson Gairns has worked on the following 10 EPO patent applications which have been published in the last five years:

EP12832680

METHODS AND COMPOSITIONS FOR TREATING, REVERSING, INHIBITING OR PREVENTING RESISTANCE TO ANTIPLATELET THERAPY

IPC classification:
A61K 31/20
Agent:
Sarah Elizabeth Roques, J A Kemp
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP12795842

COMBINATION TREATMENT OF CANCER

IPC classification:
A61K 31/519, A61P 13/08, A61P 35/00
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP13715426

HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS

IPC classification:
A61K 31/439, A61P 31/04, C07D 471/08
Applicant:
AstraZeneca AB
Agent:
Anthony James Proctor, Potter Clarkson LLP
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP13198224

Certain triazolopyrazines, compositions thereof and methods of use therefor

IPC classification:
A61K 31/437, A61K 31/4985, A61P 35/00, C07D 471/04, C07D 487/04, C07D 519/00
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13718618

CRYSTALLINE FORMS OF (S) -4-AMINO-N- (1- (4 - CHLOROPHENYL) - 3 - HYDROXYPROPYL) -1- (7H - PYRROLO [2, 3-D]PYRIMIDI N-4-YL) PIPERIDINE-4-CARBOXAMIDE

IPC classification:
A61K 31/519, A61P 35/00, C07D 487/04
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP13821906

PHARMACEUTICAL FORMULATION OF N- [5- [2-(3,5-DIMETHOXYPHENYL) ETHYL]-2H-PYRAZOL-3-YL]-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE

IPC classification:
A61K 9/16, A61K 9/20, A61K 9/46, A61K 31/496
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP15170608

CERTAIN TRIAZOLOPYRIDINES, COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CANCER.

IPC classification:
A61K 31/437, A61K 31/4985, A61P 35/00, C07D 471/04, C07D 487/04, C07D 519/00
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
EXAMINATION IN PROGRESS
EP11805575

PURINE DERIVATIVES

IPC classification:
A61K 31/522, C07D 473/18
Applicant:
AstraZeneca AB
Applicant:
Sumitomo Dainippon Pharma Co., Ltd.
Agent:
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
PATENT GRANTED
EP11805574

IMIDAZO[4,5-C]QUINOLIN-1-YL DERIVATIVE USEFUL IN THERAPY

IPC classification:
A61K 31/4188, A61K 31/4745, A61P 1/16, A61P 11/06, A61P 17/04, A61P 17/06, A61P 17/12, A61P 31/04, A61P 31/12, A61P 31/18, A61P 37/08, C07D 471/04
Applicant:
AstraZeneca AB
Applicant:
Sumitomo Dainippon Pharma Co., Ltd.
Agent:
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP15726257

METHOD FOR SUPPRESSING GLUCAGON SECRETION OF AN SGLT2 INHIBITOR

IPC classification:
A61K 31/155, A61K 31/40, A61K 31/403, A61K 31/4985, A61K 31/522, A61K 31/70, A61K 31/7042, A61K 38/28, A61P 3/10
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature